{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-25-000020","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.818554+00:00","generated_at":"2026-05-16T19:51:31.452021+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026","bullets":["Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.","FY25 gross margin 50.7% vs 42.6% in FY24; Q4 gross margin 51.3% vs 45.1%.","NGS segment revenue grew 23% to $208.1M; SynBio grew 17% to $145.0M; Biopharma grew 15% to $23.5M.","Net loss narrowed to $77.7M ($1.30/share) from $208.7M ($3.60/share); adjusted EBITDA -$46.9M vs -$93.5M.","FY2026 guidance: maintain gross margin >50%; target adjusted EBITDA breakeven by Q4 FY2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-25-000020","json":"https://secwatch.observer/filing/0001581280-25-000020.json","markdown":"https://secwatch.observer/filing/0001581280-25-000020.md","text":"https://secwatch.observer/filing/0001581280-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/0001581280-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/twist-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:51:31.452021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}